JP2024527340A5 - - Google Patents

Info

Publication number
JP2024527340A5
JP2024527340A5 JP2023581043A JP2023581043A JP2024527340A5 JP 2024527340 A5 JP2024527340 A5 JP 2024527340A5 JP 2023581043 A JP2023581043 A JP 2023581043A JP 2023581043 A JP2023581043 A JP 2023581043A JP 2024527340 A5 JP2024527340 A5 JP 2024527340A5
Authority
JP
Japan
Prior art keywords
formulation
present
amount ranging
casein
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023581043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527340A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/035870 external-priority patent/WO2023278802A1/en
Publication of JP2024527340A publication Critical patent/JP2024527340A/ja
Publication of JP2024527340A5 publication Critical patent/JP2024527340A5/ja
Pending legal-status Critical Current

Links

JP2023581043A 2021-07-01 2022-06-30 核酸の経口送達用の製剤 Pending JP2024527340A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202970P 2021-07-01 2021-07-01
US63/202,970 2021-07-01
PCT/US2022/035870 WO2023278802A1 (en) 2021-07-01 2022-06-30 Formulations for oral delivery of nucleic acids

Publications (2)

Publication Number Publication Date
JP2024527340A JP2024527340A (ja) 2024-07-24
JP2024527340A5 true JP2024527340A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=84690648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023581003A Pending JP2024525512A (ja) 2021-07-01 2022-06-30 治療用核酸及びその使用方法
JP2023581043A Pending JP2024527340A (ja) 2021-07-01 2022-06-30 核酸の経口送達用の製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023581003A Pending JP2024525512A (ja) 2021-07-01 2022-06-30 治療用核酸及びその使用方法

Country Status (8)

Country Link
US (2) US20240285668A1 (cg-RX-API-DMAC7.html)
EP (2) EP4363434A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024525512A (cg-RX-API-DMAC7.html)
KR (2) KR20240028486A (cg-RX-API-DMAC7.html)
CN (2) CN117897162A (cg-RX-API-DMAC7.html)
AU (2) AU2022303330A1 (cg-RX-API-DMAC7.html)
CA (2) CA3223495A1 (cg-RX-API-DMAC7.html)
WO (2) WO2023278802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
KR20250078993A (ko) * 2022-09-30 2025-06-04 세다르스-신나이 메디칼 센터 치료용 핵산 및 그의 사용 방법
KR20260074974A (ko) * 2023-09-15 2026-05-27 세다르스-신나이 메디칼 센터 유전독성 스트레스를 약화시키고 심장 보호 효과를 발휘하는 trex-1 증강제
WO2026035943A1 (en) 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Formulations for oral delivery of nucleic acids
WO2026035744A1 (en) 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Combination therapies for metabolic disease
KR20260065643A (ko) * 2024-10-31 2026-05-11 성균관대학교산학협력단 CU-rich RNA를 포함하는 근위축증 또는 근육 손상의 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
DK2182969T3 (en) * 2007-07-31 2017-02-27 Univ Texas Micro-RNA family that modulates fibrosis and its applications
CN102639700A (zh) * 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
US10258698B2 (en) * 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160024575A1 (en) * 2013-05-02 2016-01-28 The Regents Of The University Of California Circulating small noncoding rna markers
WO2015055857A1 (en) * 2013-10-18 2015-04-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
CA2962444C (en) * 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
WO2017136652A1 (en) * 2016-02-04 2017-08-10 Tarveda Therapeutics, Inc. Stapled peptide conjugates and particles
WO2017193051A1 (en) * 2016-05-06 2017-11-09 The Trustees Of Princeton University Methods of monitoring rnase l activity
CN111448317B (zh) * 2017-12-22 2025-07-04 罗氏创新中心哥本哈根有限公司 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
EP3749344A4 (en) * 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
US12258594B2 (en) * 2018-12-05 2025-03-25 The Broad Institute, Inc. Cas proteins with reduced immunogenicity and methods of screening thereof
WO2020131986A1 (en) * 2018-12-21 2020-06-25 Pioneer Hi-Bred International, Inc. Multiplex genome targeting
WO2026035744A1 (en) * 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Combination therapies for metabolic disease
WO2026035943A1 (en) * 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Formulations for oral delivery of nucleic acids

Similar Documents

Publication Publication Date Title
JP2023138984A (ja) Vegf-aポリペプチドをコードする改変rnaを送達するための脂質ナノ粒子
JP3566283B2 (ja) 心臓疾患の予防又は治療用の医薬組成物
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
CN113993526B (zh) 包含源自牛奶的外泌体作为有效成分的用于治疗代谢性疾病的药物组合物
US20160250290A1 (en) Gene therapy for diabetic ischemic disease
US20240285668A1 (en) Formulations for oral delivery of nucleic acids
JP2024525512A5 (cg-RX-API-DMAC7.html)
WO1997044056A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
WO2023231730A2 (zh) 使用mazdutide的治疗方法
Hemachudha et al. Letter to the Editor Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies
EP4716698A1 (en) Treatment of multiple sclerosis with anti-cd40l antibodies
JP2026063281A (ja) 薬物動態及び/又は安全性に優れるテリパラチド含有液状医薬組成物
US11987645B2 (en) Peptide for treating rheumatoid arthritis and use thereof
US20220226243A1 (en) Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same
AU747885B2 (en) Treatment of disease states
EP4041281B1 (en) Use of gdf15 for treating cardiometabolic syndrome and other conditions
RU2032422C1 (ru) Способ лечения инфаркта миокарда
JP2023538984A5 (cg-RX-API-DMAC7.html)
CN103013902B (zh) 产降钙素基因相关肽与犬钩虫抗凝肽AcAP5融合蛋白基因工程菌株及其构建方法
HERRON et al. The Use of Autolyzed Liver in the Treatment of Pernicious Anemia: A Preliminary Clinical Report
TWI309570B (cg-RX-API-DMAC7.html)
Lee et al. Chronic mucocutaneous candidiasis with candida granuloma treated with 5-fluorocytosine
WO2025208818A1 (zh) 治疗下肢外周动脉疾病的核酸分子、药物组合物及其应用
JP2025512987A5 (cg-RX-API-DMAC7.html)
MXPA98009760A (en) Therapeutic uses of bpi protein products in human beings with bleeding due to tra